Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A synthetic small molecule belonging to the chromeno[2,3-b]pyridine class. It is primarily known as an experimental compound and has been referenced as a DNA ligase inhibitor (DNA ligase-IN–2). The compound has not been approved for any therapeutic use and there are no reported clinical trials or indications. Its mechanism of action is presumed to involve inhibition of DNA ligases based on its code name and structural class. No developer or manufacturer information is available in public databases.[1][2][4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-amino-7-fluoro-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxamide.